🟢 XBI is trading 4% up today after positive Moderna-Merck melanoma-vaccine results

XBI is trading 3.99% up now at $167.26 after positive Phase 3 melanoma-vaccine results from Moderna and Merck.

• Personalized mRNA treatment met its primary recurrence-free-survival endpoint and reduced distant cancer spread versus Keytruda alone.
• Reuters called it the first positive late-stage mRNA cancer-vaccine trial; optimism spans biotechnology and mRNA drug development.
• Active August 19, 2026 regular-session trading is sector-driven, not XBI-specific; shares are sharply above the August 18 close of $160.11.